Dec 2 (Reuters) - Immunocore Holdings PLC: * IMMUNOCORE AND GADETA ANNOUNCE AGREEMENT TO DEVELOP FIRST GAMMA DELTA (ΓΔ) TCR IMMTAC FOR SOLID TUMORS * IMMUNOCORE HOLDINGS PLC - CO HAS AN OPTION FOR
Dec 2 (Reuters) - Ondine Biomedical Inc: * ONDINE REPORTS FULL RESULTS FROM PHASE 2 TRIAL * NASAL PHOTODISINFECTION STUDY MET PRIMARY ENDPOINT, STUDY ALSO MET SECONDARY ENDPOINT Source text for Eikon:
Dec 2 (Reuters) - Healthbeacon PLC: * HEALTHBEACON PLC HEALTHBEACON - HBCN - DIRECTORATE CHANGE * HEALTHBEACON PLC - LAURENCE FLAVIN, CHIEF FINANCIAL OFFICER, HAS INFORMED BOARD OF HIS INTENTION TO
Dec 2 (Reuters) - European Medicines Agency: * EMA: EMA RECOMMENDS WITHDRAWAL OF PHOLCODINE MEDICINES FROM EU MARKET: 02/12/2022 * EMA - HEALTHCARE PROFESSIONALS SHOULD CONSIDER APPROPRIATE TREATMENT
Dec 2 (Reuters) - GSK PLC : * EMA FILE ACCEPTED FOR MOMELOTINIB * EMA FILE ACCEPTED FOR MOMELOTINIB * EUROPEAN MEDICINES AGENCY ACCEPTS MARKETING AUTHORISATION APPLICATION FOR MOMELOTINIB FOR
Dec 2 (Reuters) - GSK PLC * JEMPERLI POSITIVE TRIAL IN ENDOMETRIAL CANCER * GSK: JEMPERLI (DOSTARLIMAB) RUBY PHASE III TRIAL MET ITS PRIMARY ENDPOINT * RESULTS SHOWED A STATISTICALLY SIGNIFICANT AND
Dec 2 (Reuters) - Ondine Biomedical Inc: * ONDINE REPORTS FULL RESULTS FROM PHASE 2 TRIAL * NASAL PHOTODISINFECTION STUDY MET PRIMARY ENDPOINT, STUDY ALSO MET SECONDARY ENDPOINT Source text for Eikon:
Dec 2 (Reuters) - ReNeuron Group PLC: * RENEURON GROUP PLC- HY LOSS OF £3.2 MILLION (H1 2021: LOSS OF £5.2 MILLION), REVENUE OF £438,000 (H1 2021: £58,000) Source text for Eikon: Further company
(Adds background) By Bhanvi Satija Dec 2 (Reuters) - Lapses in strategies to tackle COVID-19 this year continue to create the perfect conditions for a deadly new variant to emerge, as parts of China
(Adds Roivant Sciences, Kroger, OMERS, Campari, BlackRock, Nissan) Dec 1 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2055 GMT on Thursday: ** Biotech firm